UBS/CALL/MODERNA/140.001/0.1/21.06.24 | Real-time Bid/Ask 15:24:52 23/05/2024 BST | ||
| 2.23 CHF / 2.28 CHF | +15.05% |
|
| Current month | +988.89% | ||
| 1 month | +1,681.82% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 1.96 | +188.24% |
| 21/05/24 | 0.68 | +78.95% |
| 16/05/24 | 0.38 | +46.15% |
| 15/05/24 | 0.26 | -23.53% |
| 14/05/24 | 0.34 | +78.95% |
Delayed Quote Swiss Exchange
Last update May 22, 2024 at 04:20 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| QMRNLU | |
| ISIN | CH1312549772 |
| Date issued | 08/01/2024 |
| Strike | 140 $ |
| Maturity | 21/06/2024 (29 Days) |
| Parity | 10 : 1 |
| Emission price | 0.69 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.96 CHF |
|---|---|
| Lowest since issue | 0.1 CHF |
| Spread | 0.05 CHF |
| Spread % | 2.29% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
- Stock Market
- Warrants
- QMRNLU Warrant
